title: Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?
abstract: OBJECTIVE
  The purpose of our study was to evaluate the effectiveness of preoperative and postoperative addition of topical diclofenac to chloramphenicol/dexamethasone in patients undergoing uneventful phacoemulsification cataract surgery.
  
  
  METHODS
  Patients were randomized to (1) chloramphenicol 0.5%-dexamethasone 0.1%, 1 drop 4 times a day (n=41), or (2) chloramphenicol 0.5%-dexamethasone 0.1%, 1 drop 4 times a day, plus diclofenac 0.1%, 1 drop 3 times a day (n=38). Patients in the second group also received diclofenac 0.1% for 3 days before surgery. Topical treatment was administered for 28 days after phacoemulsification. On postoperative days 1, 14, and 28, best corrected visual acuity, macular thickness, endothelial cell density, and central corneal thickness (CCT) were measured.
  
  
  RESULTS
  The 2 groups did not have a statistically significant difference for CCT, endothelial cell density, macular thickness, and visual acuity at the 3 time points of the follow-up period.
  
  
  CONCLUSIONS
  The addition of diclofenac did not seem to offer any additional benefit after uneventful phacoemulsification.
authors.affiliation: Department of Ophthalmology, University of Athens, 28 Papanastasiou street, Athens, Greece.
authors.forename: Marilita M
authors.initials: MM
authors.lastname: Moschos
authors.forename: Irini P
authors.initials: IP
authors.lastname: Chatziralli
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Pantazis
authors.forename: Alexandros A
authors.initials: AA
authors.lastname: Rouvas
authors.forename: Theodoros N
authors.initials: TN
authors.lastname: Sergentanis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D002386:Cataract; D002452:Cell Count; D002701:Chloramphenicol / Q000627:therapeutic use; D003315:Cornea / Q000187:drug effects / Q000473:pathology; D003907:Dexamethasone / Q000627:therapeutic use; D004008:Diclofenac / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D004728:Endothelium, Corneal / Q000187:drug effects / Q000473:pathology; D005260:Female; D005584:Fovea Centralis / Q000473:pathology; D006801:Humans; D008266:Macula Lutea / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification / Q000379:methods*; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D004008:Diclofenac; D002701:Chloramphenicol; D003907:Dexamethasone